60 related articles for article (PubMed ID: 21586199)
1. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.
de Menthon M; Cohen P; Pagnoux C; Buchler M; Sibilia J; Détrée F; Gayraud M; Khellaf M; Penalba C; Legallicier B; Mouthon L; Guillevin L
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S63-71. PubMed ID: 21586199
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
Keogh KA; Ytterberg SR; Fervenza FC; Carlson KA; Schroeder DR; Specks U
Am J Respir Crit Care Med; 2006 Jan; 173(2):180-7. PubMed ID: 16224107
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.
Habibi MA; Alesaeidi S; Zahedi M; Hakimi Rahmani S; Piri SM; Tavakolpour S
Biology (Basel); 2022 Dec; 11(12):. PubMed ID: 36552276
[No Abstract] [Full Text] [Related]
4. Updates of ocular involvement in granulomatosis with polyangiitis.
Mei L; Wang L; Yan H
Graefes Arch Clin Exp Ophthalmol; 2023 Jun; 261(6):1515-1523. PubMed ID: 36473987
[TBL] [Abstract][Full Text] [Related]
5. Infliximab therapy of relapsing tracheal stenosis in a pediatric patient with granulomatosis with polyangiitis: a case report.
Schnell A; Ruppel R; Tremel C; Galiano M; Meßbacher ME; Krickau T
J Med Case Rep; 2022 Apr; 16(1):129. PubMed ID: 35361259
[TBL] [Abstract][Full Text] [Related]
6. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.
Nozaki Y
Front Immunol; 2021; 12():631055. PubMed ID: 33868250
[TBL] [Abstract][Full Text] [Related]
7. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).
Terrier B; Darbon R; Durel CA; Hachulla E; Karras A; Maillard H; Papo T; Puechal X; Pugnet G; Quemeneur T; Samson M; Taille C; Guillevin L;
Orphanet J Rare Dis; 2020 Dec; 15(Suppl 2):351. PubMed ID: 33372616
[TBL] [Abstract][Full Text] [Related]
8. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
9. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Y; Nakayamada S; Kubo S; Ishikawa Y; Yoshikawa M; Sakata K; Iwata S; Miyagawa I; Nakano K; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):141. PubMed ID: 32539843
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Schreiner J; Steiner UC; Vultaggio A; Matucci A; Crowley C; Boyman O
Front Immunol; 2019; 10():1990. PubMed ID: 31555262
[No Abstract] [Full Text] [Related]
11. Remicade
Melsheimer R; Geldhof A; Apaolaza I; Schaible T
Biologics; 2019; 13():139-178. PubMed ID: 31440029
[TBL] [Abstract][Full Text] [Related]
12. Biologics for childhood systemic vasculitis.
Akamine K; Punaro M
Pediatr Nephrol; 2019 Nov; 34(11):2295-2309. PubMed ID: 30203375
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.
Taha R; El-Haddad H; Almuallim A; Alshaiki F; Obaid E; Almoallim H
Open Access Rheumatol; 2017; 9():201-214. PubMed ID: 29290695
[TBL] [Abstract][Full Text] [Related]
14. [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].
Schirmer JH; Aries PM; de Groot K; Hellmich B; Holle JU; Kneitz C; Kötter I; Lamprecht P; Müller-Ladner U; Reinhold-Keller E; Specker C; Zänker M; Moosig F
Z Rheumatol; 2017 Nov; 76(Suppl 3):77-104. PubMed ID: 29204681
[No Abstract] [Full Text] [Related]
15. Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?
McAdoo SP; Pusey CD
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i80-i88. PubMed ID: 28391344
[TBL] [Abstract][Full Text] [Related]
16. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.
Plumb LA; Oni L; Marks SD; Tullus K
Pediatr Nephrol; 2018 Jan; 33(1):25-39. PubMed ID: 28062909
[TBL] [Abstract][Full Text] [Related]
17. Management of Small Vessel Vasculitides.
Lopalco G; Rigante D; Venerito V; Emmi G; Anelli MG; Lapadula G; Iannone F; Cantarini L
Curr Rheumatol Rep; 2016 Jun; 18(6):36. PubMed ID: 27118389
[TBL] [Abstract][Full Text] [Related]
18. An update of neurological manifestations of vasculitides and connective tissue diseases: a literature review.
Bougea A; Anagnostou E; Spandideas N; Triantafyllou N; Kararizou E
Einstein (Sao Paulo); 2015; 13(4):627-35. PubMed ID: 26313435
[TBL] [Abstract][Full Text] [Related]
19. [Treatment strategies for ANCA-associated vasculitides].
Hellmich B
Z Rheumatol; 2015 Jun; 74(5):388-97. PubMed ID: 26031284
[TBL] [Abstract][Full Text] [Related]
20. Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases.
Bitik B; Kılıç L; Küçükşahin O; Şahin K; Tufan A; Karadağ Ö; Pay S; Ateş A; Ucar M; Tutar H; Karaaslan Y; Yilmaz S; Ertenli AI; Konuk O; Turgay M; Goker B
Rheumatol Int; 2015 Jun; 35(6):1083-92. PubMed ID: 25413843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
